Table 1.
Demographic data of the study participants
| Chemotherapy group (n = 16) | Healthy controls (n = 14) | |||
|---|---|---|---|---|
| Variable | Number | Percent | Number | Percent |
| Age, years | ||||
| Mean (SD) | 67.0 (5.39) | N/A | 67.8 (5.24) | N/A |
| Range | 60–82 | N/A | 60–78 | N/A |
| Race | ||||
| White | 11 | 68.8% | 14 | 100% |
| Black | 5 | 31.2% | 0 | 0.0% |
| Ethnicity | ||||
| Hispanic or Latina | 2 | 12.5% | 2 | 14.3% |
| Non-Hispanic | 14 | 87.5% | 12 | 85.7% |
| Education | ||||
| High school | 4 | 25.0% | 1 | 7.1% |
| Some college or junior college | 6 + 2 | 50.0% | 4 + 4 | 57.1% |
| College degree | 3 | 18.8% | 3 | 21.4% |
| Post college | 1 | 6.2% | 2 | 14.4% |
| Stage | ||||
| I | 5 | 31.3% | N/A | N/A |
| II | 8 | 50.0% | N/A | N/A |
| III | 3 | 18.7% | N/A | N/A |
| Regimen | ||||
| TC | 7 | 43.75% | N/A | N/A |
| TCPH | 1 | 6.25% | N/A | N/A |
| Paclitaxel/trastuzumab | 4 | 25.0% | N/A | N/A |
| Docetaxel/cyclophosphamide/PH | 1 | 6.25% | N/A | N/A |
| Carboplatin/paclitaxel | 1 | 6.25% | N/A | N/A |
| ddAC – paclitaxel | 1 | 6.25% | N/A | N/A |
| TAC | 1 | 6.25% | N/A | N/A |
Abbreviations: TC docetaxel and cyclophosphamide, TCPH docetaxel, carboplatin, pertuzumab, trastuzumab, Docetaxel/cyclophosphamide/PH docetaxel, cyclophosphamide, pertuzumab, trastuzumab, ddAC - Paclitaxel dose-dense doxorubicin and cyclophosphamide followed by paclitaxel, TAC docetaxel, doxorubicin, and cyclophosphamide, N/A not applicable